降脂药物运用于结直肠癌治疗中的研究进展

公 绪宁1, 张 赟政1, 徐 广懋1, 杨 振1, 刘 建刚1, 陶 鸽如2
1、山东第一医科大学第二附属医院胃肠外科
2、山东第一医科大学天外村校区中心实验室

摘要


结直肠癌（Colorectal cancer，CRC）是十分常见且研究充分的肠道上皮源性恶性肿瘤，但目前其发病机制
尚未完全厘清[1]。已有明确的证据表明，CRC的发生发展必然伴随着肿瘤脂质代谢的异常，即多种酶、蛋白质及信
号分子表达失调，进而通过促进脂质摄取、合成及脂滴蓄积诸种方式促进CRC增殖、生长及转移[2]。因此，干预脂
质代谢已经成为CRC治疗的新方向。他汀类药物、前蛋白转化酶枯草杆菌蛋白酶/kexin 9型（PCSK9）抑制剂及依
折麦布等降脂药物能直接、有效地降低体内胆固醇及脂肪酸水平，从而抑制CRC的生长、增殖及转移。故而本文对
CRC中脂质代谢异常的特征及降脂药物的抗肿瘤作用做系统、有逻辑性的综述，也由此自然地引出对CRC临床治
疗的新思路。

关键词


结直肠癌；降脂药物；他汀类药物；脂肪酸

全文:

PDF


参考


[1]Guo C, Zhang L, Zhao M, et al. Targeting lipid

metabolism with natural products: A novel strategy for

gastrointestinal cancer therapy. Phytother Res. 2023;37(5):2036-

2050. doi:10.1002/ptr.7735;

[2]Bray F, Ferlay J, Soerjomataram I, Siegel RL, Torre

LA, Jemal A.Global cancer statistics 2018: GLOBOCAN

estimates of incidence and mortality worldwide for 36 cancers

in 185 countries. CA 32Cancer J Clin. 2018;68(6):394-424.

[3]W. Yu, Q. Lei, L. Yang, et al.,“Contradictory Roles

of Lipid Metabolism in Immune Response Within the Tumor

Microenvironment, ”Journal of Hematology and Oncology 14,

no. 1 (2021): 187

[4]Hassanabad AF. Current perspectives on statins

as potential anticancer therapeutics: clinical outcomes and

underlying molecular mechanisms. Transl Lung Cancer Res.

2019;8:692.

[5]G. Pascual, A.Avgustinova, S.Mejetta, et al.,

“Targeting MetastasisInitiating Cells Through the Fatty Acid

Receptor Cd36, ”Nature 541, no. 7635 (2017): 41-45.

[6]A. Nath, I. Li, L. R. Roberts, and C. Chan,“ElevatedFree Fatty Acid Uptake via CD36 Promotes EpithelialMesenchymal Transition in Hepatocellular Carcinoma, ”

Scientific Reports 5, no. 1 (2015): 14752.

[7]F. Geng, X. Cheng, X. Wu, et al.,“Inhibition of

SOAT1 Suppresses Glioblastoma Growth via Blocking SREBP-

1-Mediated Lipogenesis, ”Clinical Cancer Research 22, no. 21

(2016): 5337-5348.

[8]M. T. Snaebjornsson, S. Janaki-Raman, and A. Schulze,

“Greasing the Wheels of the Cancer Machine: The Role of

Lipid Metabolism in Cancer, ”Cell Metabolism 31, no. 1 (2020):

62-76.

[9]X. Zhu, X. Ying, Y. Liu, et al.,“Stability and

Variability of Molecular Subtypes: Comparative Analysis

of Primary and Metastatic TripleNegative Breast Cancer, ”

Cancer Biology and Medicine 21, no. 9 (2024): 784-798.

[10]W. W. Feng, H. T. Zuppe, and M. Kurokawa,

“The Role of CD36 in Cancer Progression and Its Value as a

Therapeutic Target, ”Cells 12, no. 12 (2023): 1605.

[11]L. Xia, Z. Zhou, X. Chen, et al.,“LigandDependent CD36 Functions in Cancer Progression, Metastasis,

Immune Response, and Drug Resistance, ”Biomedicine and

Pharmacotherapy 168 (2023): 115834.

[12]Tong L, Feng P, Jing Y, et al. LC-MS-based lipid

profile in colorectal cancer patients: TAGs are the main disturbed

lipid markers of colorectal cancer progression. [J]. Analytical and

bioanalytical chemistry, 2019, 411(20): 5079-5088.

[13]XIAO Y，LIU Q，PENG N，et al. Lovastatin

Inhibits RhoA to Suppress Canonical Wnt/β -Catenin

Signaling and Alternative Wnt-YAP/TAZ Signaling in Colon

Cancer [J]. Cell Transplant，2022，31：9636897221075749.


Refbacks

  • 当前没有refback。